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When the error rate during the copying of genetic material exceeds a threshold value, the genetic information
cannot be maintained. This concept is the basis of a new antiviral strategy termed lethal mutagenesis or virus
entry into error catastrophe. Critical for its success is preventing survival of residual infectious virus or virus
mutants that escape the transition into error catastrophe. Here we document that mutated, preextinction
foot-and-mouth disease virus (FMDV) RNA can interfere with and delay viral production up to 30 h when
cotransfected in BHK-21 cells with standard RNA. Interference depended on the physical integrity of preex-
tinction RNA and was not observed with unrelated RNAs or with nonmutated, defective FMDV RNA. These
results suggest that this type of interference requires large size, preextinction FMDV RNA and is mediated
neither by small interfering RNAs nor by RNAs that can compete with infectious RNA for host cell factors. A
model based on the aberrant expression of mutated RNA as it is expected to occur in the initial stages of the
transition into error catastrophe is proposed. Interference mediated by preextinction RNA indicates an
advantage of mutagenesis versus inhibition in preventing the survival of virus escape mutants during antiviral
treatments.
High mutation rates and quasispecies dynamics (17, 21, 23)
confer great adaptability to RNA viruses and represent a major
obstacle for the prevention and control of RNA viral diseases
(17, 25). However, theoretical studies have provided evidence
that for any replication system there is a maximum error rate
compatible with maintenance of the information encoded in
the replicating genome (2, 22, 23, 37, 46). The larger the
complexity of the genome, the higher the copying fidelity
needed to maintain the encoded information. The irreversible
transition into loss of genetic information is termed entry into
error catastrophe, and the critical average error rate at the
transition point is the error threshold (2, 22, 23, 37, 46). This
concept has encouraged research in a new antiviral strategy
termed lethal mutagenesis (12, 22, 29, 32). In the case of
viruses, crossing the error threshold should result in a transi-
tion from a productive to an abortive infection. Virus extinc-
tion associated with enhanced mutagenesis has been docu-
mented with a variety of virus-host systems (1, 12, 13, 27, 29,
31–34, 39, 43, 44; for reviews, see references 16, 22, and 26),
including prevention of the establishment of a persistent lym-
phocytic choriomeningitis virus (LCMV) infection in vivo (42).
Studies with the animal picornavirus foot-and-mouth disease
virus (FMDV) in cell culture have established that virus ex-
tinction through enhanced mutagenesis is favored by low viral
load and low viral fitness (44). As a consequence, combination
treatments involving a mutagenic agent and antiviral inhibitors
were more effective than a mutagenic agent alone in driving
FMDV to extinction (39). When the mutagenic activity was
insufficient for a given fitness level of FMDV, inhibitor-resis-
tant, extinction-escape mutants of FMDV were selected (38).
Selection of inhibitor-escape mutants of viruses is a major
cause of failure of antiviral treatments based on the adminis-
tration of inhibitors (15, 20, 35, 41). Quasispecies dynamics
suggest an experimentally testable advantage of an error ca-
tastrophe-based antiviral approach, consisting of the adverse
effect of a highly-mutated-mutant spectrum on any residual
viral infectivity remaining in the infected cell. De la Torre and
Holland (14) showed that a standard mutant spectrum of ve-
sicular stomatitis virus (VSV) could suppress the infectivity of
VSV mutants of superior fitness. We hypothesized that this
effect should also occur with a mutant spectrum on its way to
extinction and that such a spectrum should hinder progression
of infection by residual nonmutated RNA. Here we report
RNA cotransfection experiments that show that preextinction
FMDV RNA interferes with infectious FMDV RNA. Interfer-
ence was not observed with unrelated RNAs, with an unmu-
tated defective FMDV RNA with a deletion of 417 nucleo-
tides, or with the same preextinction RNA reduced in size by
mild alkaline treatment. The results identify an advantage of
mutagenesis as an antiviral strategy through suppression of
residual infectivity by complex mutant spectra produced near
the transition into error catastrophe.
MATERIALS AND METHODS
Cells, viruses, and infections. The origin and growth conditions of BHK-21
cells have been previously described (18, 45). FMDV C-S8c1 is a biological clone
of natural isolate C-Sta Pau-Spain 70, obtained as previously described (45).
Infections in liquid culture medium and plaque assays in semisolid agar medium
were done as previously described (18, 45). Mock-infected cells and serial infec-
tions with supernatants of mock-infected cells were maintained in parallel during
FMDV infections to control for the absence of viral contamination.
Infectious center plaque assay. Different amounts of C-S8c1 RNA (107 to 1011
molecules) and preextinction RNA genomes (107 to 1010 molecules) were elec-
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troporated into 1.2 106 BHK-21 cells. Electroporated cells were serially diluted
in PBS, and each diluted cell suspension was added to 35-mm plates containing
BHK-21 cells at 80% confluence and incubated at 37°C for 2 h in 7% CO2. Then
semisolid agar medium was added, and the cells were incubated for another 48 h
before staining for plaque counting (5, 18, 45). Control experiments confirmed
that, as expected, cellular RNA did not induce plaque formation.
Mutagenic and antiviral treatments. 5-fluorouracil (FU) was used as the
mutagenic base analog, and guanidine hydrochloride (G) was used as the inhib-
itor of FMDV replication, as previously described (38, 39, 44). FU medium
contained FU (200 g/ml), and FUG medium contained FU (200 g/ml) and G
(4 mM). Solutions were sterilized by filtration and stored a maximum of 15 days.
All media were supplemented with 2% fetal calf serum. The effect of medium
with FU and FUG on cell viability and control experiments to ascertain that virus
extinction was not due to the toxicity of FUG were described previously (39, 44).
Infections in the presence of FUG were performed as previously described (37,
38). The passage number is indicated by p (i.e., C-S8c1 FUGp1 is passage 1 of
FMDV C-S8c1 in FUG medium). To test for virus extinction, serial infections
and blind passages in the absence of FU and G were carried out as previously
described (39). The number of cells involved in infection and the multiplicity of
infection for each experiment are indicated in the corresponding figure legends.
Viral and cellular RNAs. Viral RNA was extracted from the medium of
infected or electroporated cultures as previously described (44) and quantitated
with Light Cycler instruments (Roche) by using the Light Cycler RNA Master
SYBR Green I kit (Roche) according to the manufacturer’s instructions with
purified FMDV C-S8c1 RNA as a standard. Three FMDV genomic regions were
subjected to RNA quantification: residues 3175 to 3518 (within the VP1-coding
region), residues 4318 to 4767 (within the 2C-coding region), and residues 6610
to 7156 (within the 3D-coding region). Low-molar-mass preextinction viral RNA
was obtained by incubation of preextinction RNA with 200 mM sodium bicar-
bonate (pH 9.0) for 30 min at 90°C and neutralized by addition of the same
volume of 42 mM HEPES (pH 7.0). Radiolabeled pMT417 RNA (described
below) was treated in parallel to calibrate size reduction. The size of the RNA
was in the range of 20 to 100 nucleotides, as measured by 6% acrylamide-urea gel
electrophoresis. pMT417 RNA is a transcript from a full-length defective
FMDV RNA that has a deletion spanning residues 1153 to 1571 (9). A cDNA
copy of FMDV 417 RNA was cloned into plasmid pGEM-1 and transcribed
with SP6 RNA polymerase, as previously described (50; J. F. García-Arriaza, E.
Domingo, and C. Escarmı´s, unpublished data). Human immunodeficiency virus
(HIV) pol RNA is a 141-residue-long RNA transcribed by using T3 RNA poly-
merase (8) from pBluescript SK() containing a 66-bp fragment spanning nu-
cleotides 1629 to 1692 from the start of the HIV pol open reading frame (51). A
mixture of 23S and 16S Escherichia coli rRNA (Roche) was used as a nonviral
RNA control in coelectroporation experiments.
Cell electroporation. BHK-21 cell monolayers were detached, washed with
electroporation buffer (21 mM HEPES [pH 7.0], 137 mM NaCl, 5 mM KCl, 0.7
mM Na2HPO4, 6 mM glucose), and introduced in a 0.4-cm cuvette (Bio-Rad).
RNA (0.05 to 5.5 ng) was electroporated into 1.2  106 cells by applying a pulse
of 280 V, 250 F, and 400 with a Bio-Rad gene pulser. Under these conditions,
the proportion of BHK-21 cells expressing 3D antigen (detected with a mono-
clonal antibody 3H11 specific for FMDV 3D) at 18-h postelectroporation with
100 C-S8c1 RNA molecules per cell was 30%. Electroporated cells were incu-
bated in 25-cm flasks in Dulbecco’s modified Eagle’s medium (DMEM) with
10% fetal calf serum at 37°C in 7% CO2 for 4 h. The medium was then removed
and replaced by DMEM with 2% calf serum. At different times postelectropo-
ration, aliquots of culture supernatant were assayed for the presence of FMDV
or interferon.
Interferon assay. Intracellular and extracellular interferon (IFN) levels pro-
duced by BHK-21 cells transfected with preextinction RNA were quantitated by
a cytopathic-effect inhibition assay using VSV infection of BHK-21 cells and
murine alpha IFN and L929 cells as the positive controls (11).
Molecular cloning and nucleotide sequencing. Nucleotide sequencing of re-
verse transcription (RT)-PCR products, molecular cloning into pGEM-4Z, and
nucleotide sequencing of individual clones were carried out as previously de-
scribed (3, 24, 38, 44). The regions sequenced corresponded to residues 3193 to
3869 (VP1-coding region) and 6609 to 8035 (3D-coding region). To ensure that
sequences of individual clones represented different genomes from the mutant
spectrum, an excess template for the RT-PCR amplification was ascertained by
amplification of dilutions of the template preparations as detailed by Airaksinen
et al (1). Mutation frequencies were calculated as previously described (3, 24, 38,
44).
RESULTS
Kinetics of FMDV production upon electroporation with
viral RNA. Preextinction FMDV C-S8c1 RNA was obtained by
passage of the virus in the presence of FUG, as detailed in
Materials and Methods (Fig. 1). The mutation frequency of its
mutant spectrum was 3.9  104 and 7.1  104 substitutions
per nucleotide for the VP1- and 3D-coding regions, respec-
tively. These values were 2.6 and 3.3 times higher than those
for the control populations passaged in parallel in the absence
of mutagens. No differences between the consensus nucleotide
sequences of preextinction RNA and those of the parental
C-S8c1 RNA were observed. Mutation frequencies and the
invariance of consensus sequences are in agreement with pre-
vious characterizations of preextinction FMDV RNA (39, 44).
To compare the capacities of FMDV C-S8c1 RNA and of
increasingly mutagenized C-S8c1 RNA to produce infectious
progeny, equivalent amounts of RNA were electroporated into
BHK-21 cells and the FMDV titers in the supernatant of elec-
troporated cell cultures were determined at different times up
to 45-h postelectroporation (Fig. 2). Based on an average of 50
preextinction RNA genome molecules per cell, no detectable
FMDV production occurred up to 44-h postelectroporation
(Fig. 2). Based on an average of 103 preextinction RNA ge-
nome molecules per cell, virus production was detected at 30-h
postelectroporation, and the virus titer at 30- to 40-h postelec-
troporation was 104-fold lower than the titer produced by an
equal amount of C-S8c1 RNA (Fig. 2). This observed viral
production is possible because of the absence of mutagens in
the medium employed in these assays. At 50-h postelectropo-
ration and at later times in which at least a second round of
FIG. 1. Preparation of preextinction FMDV RNA. BHK-21 cells (1
 107) were infected with 5  105 PFU of FMDV C-S8c1 in either
DMEM or FUG medium. Subsequent infections were carried out,
infecting 1  107 BHK-21 cells with 0.5 ml of the culture supernatant
of the previous infection. Virus production was determined at each
passage. The multiplicity of infection can be calculated from the virus
titer shown in ordinate. The preextinction population (that preceding
the population from which no infectivity or RT-PCR-amplifiable
FMDV genomic material could be rescued after three blind passages
in DMEM) (38, 39, 44) is indicated by an arrow. Titration was carried
out in triplicate, and standard deviations (not shown) never exceeded
25%. The procedures are detailed in Materials and Methods.
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infection of BHK-21 cells had taken place (45), differences in
titers decreased substantially (data not shown). Progeny pro-
duced upon electroporation of C-S8c1FUGp1 RNA and
C-S8c1FUGp2 RNA was intermediate between the production
by unmutated, parental C-S8c1 RNA and preextinction RNA
(Fig. 2). Thus, viral production upon electroporation of
BHK-21 cells with FMDV RNA decreased as the viral popu-
lation from which the RNA was obtained approached extinc-
tion.
Electroporation of 1.2  106 BHK-21 cells with 1010 mole-
cules of C-S8c1 RNA produced a total of 104 infectious cen-
ters, whereas no infectious centers could be detected after
electroporation with the same amount of preextinction RNA.
Thus, independent assays indicate a very low specific infectivity
(PFU per genomic RNA molecule) of preextinction FMDV
RNA, which in an infectious center assay was at least 104-fold
lower than that of FMDV C-S8c1 RNA.
Interference of preextinction RNA with the infectivity of
C-S8c1 RNA. To test whether a preextinction RNA population
could exert a suppressive effect on the replication of standard
FMDV C-S8c1 RNA, BHK-21 cells were electroporated with
either C-S8c1 RNA or preextinction RNA or with mixtures of
C-S8c1 RNA and either preextinction RNA or other related
and unrelated RNAs in different proportions (Fig. 3). In three
independent experiments, 1.2  108 C-S8c1 RNA molecules
were electroporated into 1.2  106 BHK-21 cells, either alone
or with 1.2  107 (Fig. 3A), 1.2  108 (Fig. 3B), or 1.2  109
(Fig. 3C) molecules of preextinction RNA or other related and
unrelated RNAs. In all cases, the presence of preextinction
RNA delayed by 30- to 40-h postelectroporation the produc-
tion of viral progeny. At early times postelectroporation, viral
production by the cells cotransfected with C-S8c1 RNA and
preextinction RNA was similar or lower than viral production
by preextinction RNA alone (Fig. 2 and 3). To gain insight into
the possible mechanisms involved in interference by preextinc-
tion RNA, cotransfection with the same amounts of unrelated
RNAs, namely E. coli rRNA and an HIV-1 transcript (de-
scribed in Materials and Methods) was carried out in parallel.
No interference was detected (Fig. 3), indicating that interfer-
ence was not due to some nonspecific effect associated with
perturbations derived from the penetration of foreign RNAs
into BHK-21 cells. To determine whether competition for cel-
lular factors could be the major determinant of interference,
cotransfection of C-S8c1 RNA with a variant FMDV C-S8c1
RNA that included a 417-nucleotide deletion (417, spanning
FMDV C-S8c1 genomic residues 1153 to 1571 within the L-
coding region) (9) was carried out. This defective RNA main-
tains the open reading frame to produce the FMDV polypro-
tein; its replication can be complemented by standard C-S8c1,
is packaged into capsids, and in mixed infections can contrib-
ute VP1 protein for the particles of the complementing FMDV
(9). No interference was observed with 417 RNA, suggesting
that competition between viral RNAs for host cell factors is not
a major determinant of the suppressive activity of preextinc-
tion RNA. To determine whether large preextinction RNA
was necessary for the interfering activity, preextinction RNA
was treated with a mild alkaline solution to produce a product
heterogeneous in size, in the range of 20 to 100 nucleotides
(details given in Materials and Methods). No interference was
observed with equivalent proportions of small preextinction
RNA compared with that for full-size preextinction RNA (Fig.
3). This result suggests that short RNA segments that could
either provide small interfering RNAs, trigger unspecific cel-
lular responses, or supply some inhibitor into the cells did not
play a major role in interference by preextinction RNA. To
ascertain that preextinction RNA did not elicit some unspecific
antiviral state such as IFN production, the amount of intracel-
lular and extracellular IFN in BHK-21 cells transfected with
preextinction RNA was measured with a cytopathic-effect in-
hibition assay using VSV. The amount of IFN measured both
intracellularly and extracellularly was 1.5 unit equivalents of
murine IFN/ml, suggesting that neither IFN nor any other
unspecific interfering activity was a significant component of
the interference produced by preextinction FMDV RNA. We
conclude that preextinction viral RNA can interfere with in-
fectivity of viral RNA and that the interference is not triggered
by unspecific responses of the cell to foreign RNA.
FIG. 2. Virus production upon electroporation of BHK-21 cells with FMDV RNA. BHK-21 cells (1.2  106) were electroporated with either
6  107 molecules (left panel) or 1.2  109 molecules (right panel) of the indicated RNAs. FUG p1 RNA, FUG p2 RNA, and preextinction RNA
are FMDV C-S8c1 RNA after one, two, or three passages, respectively, in FUG medium (shown in Fig. 1). At the indicated hours postelectro-
poration, aliquots of the culture medium were withdrawn and titrated in triplicate. Standard deviations (not shown) never exceeded 25%. The
procedures are detailed in Materials and Methods.
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DISCUSSION
Genetic variation of RNA viruses through mutation, homol-
ogous and nonhomologous recombination, and genome seg-
ment reassortment constitutes a major difficulty for disease
prevention and control (16, 17, 19). Difficulties arise from
adaptability, which has its origins in the continuous production
of mutant genomes, which favors a process of competition and
selection of those mutant distributions best adapted to a given
environment (17, 21). Quasispecies dynamics has several bio-
logical manifestations. Failure of an antiviral immune response
to clear virus may be associated with the presence of anti-
body—or cytotoxic T cell—escape mutants of a virus (30, 47,
48, 52). Mutant spectra of viral quasispecies may also include
mutants with altered cell tropism and host range, with obvious
implications for viral disease emergence (for a review, see
reference 4). Of direct relevance to therapy using antiviral
inhibitors is the frequent (at times systematic) selection of
inhibitor-resistant mutants (for a review, see references 15, 20,
35, and 41), which is a major cause of treatment failure, a
justification for combination therapy (17, 28), and an incentive
to investigate virus entry into error catastrophe as a new anti-
viral strategy (16, 22).
In virus population dynamics, there is a fundamental differ-
ence between antiviral approaches based on the inhibition of
viral replication and those based on enhanced mutagenesis. In
the former, virus mutant distributions showing decreased sen-
sitivity to one or several inhibitors are endowed with a selective
advantage in the presence of the inhibitors, such that, notwith-
standing possible suppressive effects of mutant spectra (14, 49),
they can build new, dominant mutant distributions manifesting
some degree of resistance to the inhibitor(s). Despite possible
fitness costs associated with the resistance mutations, further
replication generates either additional mutations that
strengthen the resistance phenotype or compensatory muta-
tions that, while maintaining the same level of resistance to
inhibitors, contribute increases in viral fitness (7, 36). In con-
trast, in the transition towards error catastrophe, either resid-
ual infectivity or, possibly, viruses showing resistance to the
mutagens or inhibitors used (40, 53) encounter a highly com-
plex mutant spectrum that may interfere with replication of
viable RNA. In the preextinction populations obtained upon
serial infections with FUG, the proportion of infectious RNA
molecules was 2.5  107 of the total, as determined by light-
cycler RT-PCR (38).
FIG. 3. Virus production upon electroporation of FMDV C-S8c1 RNA with related or unrelated RNAs. The data shown in panels A, B, and
C are derived from the results of parallel, independent experiments. The symbols that identify the RNAs used in electroporation or coelectro-
poration are shown in the box to the right. In all cases, 1.2 106 BHK-21 cells were electroporated with 1.2 108 molecules of C-S8c1 RNA alone
or 1.2  108 molecules of preextinction RNA alone. In coelectroporation involving standard preextinction RNA, 1.2  108 molecules of C-S8c1
RNA were coelectroporated with 1.2  107 molecules (A), 1.2  108 molecules (B), or 1.2  109 molecules (C) of preextinction FMDV C-S8c1
RNA (prepared as described in the legend to Fig. 1). The additional, parallel coelectroporation involved mixtures of 1.2 108 molecules of FMDV
C-S8c1 and 1.2  107 molecules (A), 1.2  108 molecules (B), or 1.2  109 molecules (C) of the indicated viral or cellular RNAs. At the indicated
times postelectroporation, aliquots of the culture medium were withdrawn and titrated in triplicate. Standard deviations (not shown) never
exceeded 25%. The origin and quantification of the different RNAs used and the procedures for cell electroporation and culture of electroporated
cells are described in Materials and Methods.
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Suppressive effects of mutant spectra were documented ex-
perimentally with VSV in cell culture (14), with variants of
LCMV in vivo (49), and with live poliovirus vaccines (10). The
interference of preextinction RNA on the replication of infec-
tious virus RNA underlines an advantage of enhanced mu-
tagenesis versus inhibition as an antiviral strategy. The ob-
served interference was specifically associated with full-length,
mutated, preextinction RNA, suggesting that it may be the
expression (normal or aberrant) of altered proteins that jeop-
ardizes the replication capacity of residual infectious RNA.
The expression of altered proteins may occur through trans-
acting functions such as those of modified capsid proteins that
are not properly assembled with standard nonmutated proteins
or modified proteases (L or 3C) that may compete with their
wild-type counterparts for the processing of cellular factors or
the FMDV polyprotein (6). The interference by preextinction
RNA was not dose dependent. A more-pronounced delay in
the rise of viral infectivity was observed with the lowest ratio of
preextincion RNA to C-S8c1 RNA tested (Fig. 3). The absence
of a dose effect is not easy to interpret, since preextinction
RNA is a complex mixture of RNAs showing different degrees
of infectivity and capacity to gain fitness. Therefore, they differ
regarding their contribution to infectious progeny upon repli-
cation in the absence of mutagens and inhibitors (37, 38, 43).
Upon transfection, these evolving complex mixtures can con-
tribute both to interference and to infectivity in addition to the
infectivity of C-S8c1 RNA, as observed upon transfection with
preextinction RNA alone (Fig. 2 and 3). Dose-dependent in-
terference by preextinction RNA would be expected only if an
invariable interfering activity were the only component co-
transfected with C-S8c1 RNA. A potential application of the
transition into error catastrophe as an antiviral strategy will
necessitate mutagenic agents specific for viral polymerases that
provide effective concentrations at all viral replication sites.
The results with FMDV encourage the use of compatible com-
binations of mutagens and inhibitors either to achieve viral
extinction or to diminish the viral load to permit virus clear-
ance by the host immune response. The latter should be fa-
vored by the interference effects of the mutant spectra de-
scribed here.
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